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Abstract
Background: The prevalence of Chronic Obstructive Pulmonary Disease (COPD) in many developed
countries appears to be increasing. There is some evidence from Latin America that COPD is a growing
cause of death, but information on prevalence is scant. It is possible that, due to the high frequency of
smoking in these countries, this disease may represent a major public health problem that has not yet been
recognized as such. The PLATINO study is aimed at measuring COPD prevalence in major cities in Latin
America.
Methods/Design: A multi-country survey is being carried out in major cities in Latin America. In each
metropolitan area, a population-based sample of approximately 1,000 individuals aged 40 years or older is
being interviewed using standardized questionnaires. Eligible subjects are submitted to pre- and post-
bronchodilator spirometry, and classified according to several criteria for COPD. Anthropometric
examinations are also performed. Several risk factors are being studied, including smoking, socioeconomic
factors, exposure to domestic biomass pollution, occupational exposure to dust and hospital admissions
due to respiratory conditions during childhood. Whether or not subjects affected by COPD are aware of
their disease, and if so how it is being managed by health services, is also being investigated, as are the
consequences of this condition on quality of life and work performance.
Results: At the present time, the study is completed in São Paulo, Mexico City and Montevideo; Chile has
started the study in March 2004 and it will be followed by Venezuela; two other metropolitan areas could
still join the PLATINO project. Similar sampling procedures, with stratification for socio-economic status,
are being used in all sites. Strict coordination, training and standardization procedures have been used to
ensure comparability of results across sites. Overall 92% of the pre-bronchodilator spirometry tests
fulfilled ATS criteria of quality in the three first sites (97% in Montevideo, 91% in Mexico and 89% in Sao
Paulo).
Conclusions: The PLATINO project will provide a detailed picture of the global distribution of COPD
in Latin America. This project shows that studies from Latin America can be carried out with adequate
quality and be of scientific value.
Published: 17 June 2004
BMC Medical Research Methodology 2004, 4:15 doi:10.1186/1471-2288-4-15
Received: 13 April 2004
Accepted: 17 June 2004
This article is available from: http://www.biomedcentral.com/1471-2288/4/15
© 2004 Menezes et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL. BMC Medical Research Methodology 2004, 4:15 http://www.biomedcentral.com/1471-2288/4/15
Page 2 of 7
(page number not for citation purposes)
Background
Although Chronic Obstructive Pulmonary Disease
(COPD) is one of the most relevant public health prob-
lems in Latin America, few data are available on its preva-
lence and risk factors. Only one population-based study is
available, from a city in Southern Brazil [1]. The lack of
studies is of even greater concern in face of the high prev-
alence of smoking in the region, ranging from 11.3% in
females (Colombia) to 49.6% in males (Chile) [2-7]. For
both sexes combined, the median prevalence of smoking
from published studies is around 30%.
The burden of respiratory diseases in Latin America is also
high. According to the "Global Burden of Disease"
project, the estimated number of COPD deaths in the
Region increased from 57,000 in 1990 to 95,000 in 2000
[8]. COPD is predicted to be the fifth largest cause of dis-
ability by 2020.
The present multi-country survey, the PLATINO project
(Proyecto LatinoAmericano de Investigación en Obstruc-
ción Pulmonar), is aimed at measuring the prevalence of
COPD in some major cities of Latin America using stand-
ardized methodology. It will also provide information on
the main risk factors for this important condition.
Brief history and planning of the study
In 2001, the Latin American Thorax Association (Asoci-
ación Latinoamericana del Tórax – ALAT – Department of
COPD) decided to promote a multi-country survey to
help fill in the information gaps about COPD prevalence
and risk factors in the Region. It was initially decided that
five major cities from different countries would be
included: Sao Paulo (Brazil), Santiago (Chile), Mexico
City (Mexico), Bogota (Colombia) and Buenos Aires
(Argentina). An outline project was prepared by early
2002 and it was established that the Coordinating Centre
(CC) would be in Pelotas, Southern Brazil. Although Uru-
guay and Venezuela were not one of the countries origi-
nally involved in PLATINO, local teams became strongly
interested and both countries were included as sites of
PLATINO.
At the same time, another group of researchers was devel-
oping a similar protocol – the Burden of Obstructive Lung
Disease (BOLD) survey – to be carried out in China,
United States and other sites. It was agreed that the PLAT-
INO and BOLD teams would work together in the proto-
col to make sure that the basic methodological
approaches and data collection instruments would be
comparable for both studies.
Study organization
The organizational framework for the multi-center study
includes three committees. Representatives from ALAT,
the overall study coordinator and the principal investiga-
tors from each site make up the Steering Committee,
which has full responsibility for the design and imple-
mentation of the study. The Executive Committee
includes the overall coordinator, the coordinator for
spirometry, and the director of the ALAT department of
COPD. The Advisory Committee includes prominent
external experts on the subject who, when requested by
the Steering Committee, provide guidance on study
design, implementation and analysis.
The study secretariat and the units of epidemiology,
biostatistics and computing are located in Pelotas (Brazil).
Mexico was chosen as the site to be responsible for train-
ing and quality control of spirometric examinations. Each
study center has its own principal investigator.
Methods/Design
A cross sectional design aimed at obtaining representative
samples of adults aged 40 years or more is used. Subjects
aged less than 40 years are not included because COPD
prevalence is low in this age range [9]. Exclusion criteria
include mental disease precluding response to the ques-
tionnaire and long-term institutionalization. Individuals
temporarily admitted to a hospital when the sample was
selected are interviewed on a later occasion, after dis-
missal from hospital.
To date, the following major metropolitan areas in Latin
America are included in the study so far: Sao Paulo (Bra-
zil), Mexico City (Mexico), Montevideo (Uruguay), San-
tiago (Chile) and Caracas (Venezuela). Contacts are being
made to decide the inclusion of next sites, such as (Buenos
Aires (Argentina) and Bogotá (Colombia). These sites
were chosen because of their geographical position, pop-
ulation size and the availability of collaborating research
centers. They represent the different geographical areas of
Latin America (Figure 1) and the largest metropolitan area
in each of the selected countries.
Sample size
Calculations were based on prevalence scenarios from
published studies, with COPD prevalence ranging from 5
to 60%, a margin of error not more than four percentage
points, 95% confidence intervals, and a design effect of
1.5 based on a previous survey in the region [1]. Allowing
a 20% margin of safety for non-response, samples of
approximately 1,000 subjects in each site are required.
Sample size requirements were also calculated for detect-
ing an association between COPD and smoking (main
risk factor) using the following parameters: confidence
level of 95%, power of 80%, smoking prevalence of 30%,
relative risk of 2.0, with an additional 10% for non-
response and 15% for confounder adjustment. This calcu-
lation requires samples of 940 individuals in each site. ByBMC Medical Research Methodology 2004, 4:15 http://www.biomedcentral.com/1471-2288/4/15
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pooling data from the different sites, it will also be possi-
ble to detect smaller relative risks and to study the effect of
the risk factors discussed below.
Sampling procedure
To obtain representative samples of adults living in the
metropolitan areas of each site, a multi-stage cluster sam-
pling strategy is used. All sites use the same basic proce-
dures for sampling, with minor local adaptations as
required. Metropolitan areas are stratified into the main
city and other municipalities; further stratification
(implicit or explicit) is used for socioeconomic status var-
iables, which vary from country to country based on data
availability. Sixty-eight census tracts are selected in each
site, taking the stratification into account and using prob-
ability proportionate to the number of households in
each tract, based on the last census. Within each tract, all
households are listed and the total count is updated; the
ratio between the expected number of households and the
actual count is used to calculate the number of house-
holds to be sampled from that tract. On average, 15
households are expected to be selected from each tract,
but this number is larger for tracts where the number of
households has increased since the last census, and
smaller for tracts where it has declined. Then, systematic
sampling is used to select households from the updated
listings. All adults aged 40 years or more living in the
selected households are included in the study.
Primary outcome
The main outcome of the study is the prevalence of COPD
measured by spirometry, as defined by a post-bronchodi-
lator FEV1/FVC < 0.70. To allow comparison with other
studies, additional outcomes are also measured (Table 1).
Risk factors and COPD impact
The following risk factors are collected in all sites: sex; age
in years; skin color/ethnicity (self reported); educational
level (complete years of formal schooling) of the inter-
viewee and his/her father; occupational exposure to dust
(reported duration and frequency of exposure); smoking
history (daily amount, age at beginning and stopping,
type of cigarette, current status); passive smoking (expo-
sure at home in the previous two weeks); domestic expo-
sure to coal and biomass smoke (from cooking or
heating); hospital admissions due to a respiratory illness
during childhood; and family history of lung disease (his-
tory of chronic bronchitis, emphysema, or COPD among
parents or siblings). Anthropometric status (weight,
height, and abdominal circumference) is evaluated using
standardized methods and the instruments described
below. Body mass index (weight in kilograms / square of
height in meters) is calculated.
An additional questionnaire module addresses whether or
not subjects affected by COPD are aware of their disease,
and if so how it is being managed by health services,
including diagnostic tests, pharmacological management,
and prevention of infections. The consequences of COPD
are also investigated; including work absenteeism, hospi-
tal admissions, and disease impact on quality of life.
Instruments and examinations
The questionnaire is a composite including sections of the
following questionnaires: ATS/DLD [14], ECRHS II [15],
Lung Health Study (LHS) [16] and SF-12 [17] (to assess
overall health status). For the Brazil site, questionnaires
were written in English and then translated to Portuguese.
Study instruments were pre-tested in the Coordinating
Centre. After the last version of all instruments in English
and Portuguese, a back translation into English was done
to ensure that the content of the questions remained
unchanged. A similar procedure was used for the Spanish
version applied in the other study sites. A copy of the
questionnaire is available upon request. When a subject
refuses to participate, he/she is asked to answer a short
questionnaire including information on age, sex, smoking
and reported presence of COPD, asthma or chronic
bronchitis.
Latin American countries included in the PLATINO project  (black); and potential sites (light gray) Figure 1
Latin American countries included in the PLATINO project 
(black); and potential sites (light gray)BMC Medical Research Methodology 2004, 4:15 http://www.biomedcentral.com/1471-2288/4/15
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Height is measured with a portable Seca® stadiometer
(precision 0.1 cm) using the technique recommended by
Lohman [18]. For weight, an electronic Tanita® scale (pre-
cision 200 g) is used. For waist circumference, an inex-
tensible Fiberglass® tape (precision 0.1 cm) is used; the
measurement is taken at the midpoint between the last rib
and the iliac crest. Subjects are examined in light clothing
and without shoes. All anthropometric measurements are
carried out twice on each subject, and the average value is
used.
Spirometric examination
Subjects who, in the last three months, have had thoracic
or abdominal surgery, heart attack, eye surgery (or retinal
detachment) or hospitalization due to a cardiovascular
problem are excluded. The same applies for those under-
going tuberculosis treatment, pregnant women, or sub-
jects with a pulse rate above 120 beats/minute.
Information is also obtained on the following variables:
respiratory infection in the last three weeks; pulmonary
medication in the last three hours; smoking in the last two
hours; and vigorous exercise in the last hour. However,
these are not considered as exclusion criteria.
Measurements are taken with identical portable, battery
operated, ultrasound transit-time based EasyOne™
spirometers (Medical Technologies, Chelmsford, Massa-
chusetts and Zürich, Switzerland). Calibration is checked
daily with a three-liter syringe. Test results stored in the
spirometer memory are downloaded daily to a computer.
The initial evaluation comprises a short questionnaire to
determine whether the subject is eligible for spirometry.
Subjects then perform a maximum of 8 forced expiratory
maneuvers to obtain three ATS acceptable measurements,
with FVC and FEV1 reproducible to 150 ml. A beta agonist
bronchodilator (albuterol 200 mcg) is then administered
by inhalation through a 500 ml spacer, and the test is
repeated 15 minutes later, with the same criteria. All spiro-
metric examinations are carried out with the subject
seated, wearing a nose clip and a disposable mouthpiece.
All field methods are tested in pilot studies in each site.
Personnel, training and logistics
In each country, the local team is trained by the main
study coordinator, two experts in spirometry from Mex-
ico, the local principal investigator (PI), two to three field-
work supervisors, and a local anthropometrist.
Interviewers must have at least full secondary education.
Training lasts one week in each site, and additional time
is spent with interviewers whose performance in the
standardization sessions is sub optimal, until it becomes
satisfactory. At the end of the training period, which
includes several practical sessions, the following criteria
are used to certify that interviewers perform adequately:
• Anthropometry: acceptable levels of intra and inter-
observer variability are 1.0 cm for waist circumference and
0.2 cm for height [19].
• Spirometry: all interviewers are given the same training
for two full days, with a program fulfilling NIOSH train-
ing course in spirometry. During the two days the techni-
cians test at least 10 subjects under supervision. Finally
the technicians had to be approved in a practical
examination and awarded a certificate. Previous experi-
ence of selected technicians in spirometry was variable
Table 1: Outcome criteria in the PLATINO project.
Outcome Definition*
Spirometric criteria*
FIXED RATIO Post-bronchodilator FEV1/FVC < 70% [10]
GOLD Post-bronchodilator FEV1/FVC < 70 and FEV1 < 80% of predicted value [10]
ATS Post-bronchodilator FEV1/FVC below the 5th percentile and FEV1 < 100% of predicted value [11]
ERS Post-bronchodilator FEV1/FVC < 88% of the predicted value for men and < 89% for women [12]
Symptom-based criteria
Chronic bronchitis Cough with phlegm for at least 3 months a year in the last 2 years
Asthma Wheezing within the last 12 months
Emphysema Breathlessness due to exercise
Medical diagnosis
COPD Reported lifetime diagnosis of COPD
Chronic bronchitis Reported lifetime diagnosis of chronic bronchitis
Emphysema Reported lifetime diagnosis of emphysema
Asthma Reported lifetime diagnosis of asthma
FEV1 = forced expiratory volume in the first second; FVC = forced vital capacity For initial analyses of lung function measurements, the NHANES III 
Mexican American reference values were used [13].BMC Medical Research Methodology 2004, 4:15 http://www.biomedcentral.com/1471-2288/4/15
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depending on the site. Montevideo technicians had a uni-
versity degree in cardiorespiratory technology, a career
including training in pulmonary function testing. In Sao
Paulo, the group of technicians were respiratory physio-
therapists with no previous experience in spirometry,
whereas in Mexico, educational backgrounds were diverse
but most had been certified as spirometrists before the
survey. Neither Sao Paulo nor Mexico had formal pro-
grams to train pulmonary function technicians.
• Questionnaires: interviewers carry out an interview in
the presence of a supervisor and are approved if their per-
formance is satisfactory.
The fieldwork in each site is planned to last an average of
four months. Each study team includes on average three
scouts, 14 interviewers, three field supervisors, a local
spirometry supervisor and a secretary. The fieldwork
includes several steps:
• The first visit to the sampled households is carried out
by the scouts, who determine if there are eligible subjects
present and deliver an official letter explaining the aim of
the study. The study supervisors then contact subjects in
order to arrange the best time for the interview.
• On the scheduled day, a pair of interviewers visit the
household to apply the questionnaire and carry out all
measurements; if the subject is not available on that day,
several attempts are made until the interview and exami-
nation was completed.
• Interviewers visit the study headquarters at the begin-
ning of each workday to check the calibration of the
equipment and to receive a list of the households to be
covered. On this occasion, spirometry results obtained in
the previous day are downloaded.
Results (Quality control)
Rigorous procedures are used to ensure to standardize
data quality across sites. These include:
Spirometry
An experienced technician on pulmonary function testing
served as a field supervisor in each site and was in charge
of checking instrument calibration every day. Calibration
data is kept in the spirometer memory and database. After
each test, the automated spirometer provides an evalua-
tion of the quality of readings, based on the repeatability
of the three "best" maneuvers. The aim is to obtain a grade
"A" test according to this on-the-spot evaluation requiring
three acceptable maneuvers, with the two highest FVC and
FEV1 values within 150 ml. This is stricter than the 200 ml
required by the American Thoracic Society criteria [20].
The spirometry supervisor reviewed daily the flow-volume
and volume-time curves to check quality and provided
immediate feedback to technicians. During data collec-
tion, all spirometry results are sent weekly to Mexico using
electronic data transfer. The Mexican team analyzes
spirometry quality and provides weekly reports with
assessments of each technician. Technicians are informed
individually of their performance and their main quality
problems, in order to improve. At the same time the local
spirometry supervisor also checks these results daily
including the volume-time and flow-volume curves, and
works with the interviewers to correct any inaccuracies.
Overall 92% of the pre-bronchodilator spirometry tests
fulfilled ATS criteria of quality in the three first sites (97%
in Montevideo, 91% in Mexico and 89% in Sao Paulo). In
addition 85% of the tests reached quality grade A, that is
a reproducibility of FEV1 and FVC to 150 mL (95% in
Montevideo, 85% in Mexico and 77% in Sao Paulo). At
the end of the testing period an opportunity was given to
repeat poor quality tests. Figure 2 shows the fraction of
spirometries according to the ATS quality criteria. At least
90% of the tests were carried out on naïve subjects.
Interviews
the supervisors repeat 10% of the interviews within two
weeks after the initial contact. A short questionnaire is
used, including six questions from the main question-
naire. Kappa statistics are calculated to measure reliability.
Anthropometry
Half way through the fieldwork period, all interviewers
undergo refresher training in anthropometry, followed by
a second round of standardization sessions.
Fraction of spirometry tests fulfilling American Thoracic  Society criteria in three centers of PLATINO (Sao Paulo,  Mexico, Montevideo) Figure 2
Fraction of spirometry tests fulfilling American Thoracic 
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Data processing and analyses
All questionnaires are photocopied in each site, and the
originals sent to the CC, while a copy remains in the local
site. In the CC, all questionnaires are reviewed, open
answers are coded and data is entered twice in an Epi-Info
database [21]. The spirometry results were entered in Mex-
ico in a STATA [22] database. After spirometry results are
cleaned and edited, the database is sent to the CC and
linked to the questionnaire database. A full copy of the
final dataset is then sent to each site.
Analyses are carried out using the STATA program. These
include descriptive analyses of the prevalence of outcomes
and risk factors, as well as crude and multivariable analy-
ses. For the multivariable analyses, Poisson regression
models are used to provide estimates of adjusted preva-
lence ratios and their 95% confidence intervals [23]. All
analyses take into account the cluster sampling procedure.
Confounding variables are retained in regression models
if they reach a significance level of p = 0.20 using the Wald
test; a significance level of p < 0.05 is used for identifying
significant risk factors. Tests for linear trend are employed
as appropriate.
The first site to start the study was Sao Paulo, where data
collection took place from January to May 2003. The next
site was Mexico City, where fieldwork was carried out
from July to December 2003. Uruguay was the third site
to start the study, and data were collected from October
2003 to January 2004. Fieldwork in Santiago is expected
to start in early 2004. Additional centers will be defined
during 2004, and it is hoped that by the end of 2004 five
centers will have complete data.
Ethical considerations
Ethical approval is obtained from the ethical committee
of each participating institution. Written informed con-
sent is obtained from each subject. A T-shirt with the study
logo, as well as the disposable mouthpieces and spacers,
are presented to each subject as a souvenir of the study.
The spirometric results are mailed to each subject ten days
after the interview with an explanation of the results in lay
language. Those diagnosed with COPD or another abnor-
mality are invited to attend a medical consultation in the
participating institution. Keeping identification records




The PLATINO project will provide prevalence data on
COPD from population-based samples of large metropol-
itan areas in Latin America. It will also measure associa-
tions between COPD and selected risk factors. Although
the sample is not representative of Latin America as a
whole – which would require an extremely ambitious and
costly study – this is the first multi-center survey on this
topic encompassing multiple developing countries.
We believe that several aspects of the planning and design
of the PLATINO study have contributed to its success.
First, the close involvement of ALAT in all aspects of the
study has led to the involvement of experienced research-
ers from several countries. In particular, coordination
with BOLD makes it possible to compare findings from
the PLATINO studies with surveys performed in other
countries, since both projects have adopted the same
instruments and methodological principles. The close
coordination between these studies is an example of
mutually beneficial interaction that should be pursued by
other teams of researchers.
Second, the organization of the study is contributing to its
success under sometimes difficult conditions. By estab-
lishing a Coordinating Centre with a large experience in
epidemiological research, coordinated training and stand-
ardization of all study sites by the same team may be car-
ried out immediately prior to the beginning of field work
in each site. This tight coordination allows the sequential
initiation of data collection on a site-by-site basis (instead
of starting several sites simultaneously) and allows the
coordination team to be present at the launch of each
study. This permits lessons learned in one site to be
applied to the next surveys through early detection and
correction of identified problems. Similarly, the selection
of a single Centre exclusively for the evaluation and qual-
ity control of spirometric examinations places the same
researcher in charge of quality control for all sites. By
using electronic transmission of examination results on a
weekly basis, tight quality control of spirometry is main-
tained on a "real time" basis, and problems in this area
may be addressed as they occur. Quality of spirometries
was good, and subjects could provide spirometry tests ful-
filling ATS criteria and most of them better reproducibility
than recommended by ATS. Site variations in quality can
be attributed mostly to technicians' background, but
which no doubt includes growing experience of field
supervisors, training and central quality control.
Third, key methodological decisions contribute to the
utility of PLATINO results. The adoption of a common
sampling strategy for all sites ensures the comparability of
results across sites and allows pooled analyses. The reli-
ance on spirometry (pre- and post-bronchodilator) as the
key diagnostic method for COPD and the use of multiple
diagnostic indices ensures that results can be compared
with those from previously published surveys [24]. The
concurrent collection of anthropometric data – which is
important for diagnosing COPD – also provides popula-
tion-based information on overweight and obesity,BMC Medical Research Methodology 2004, 4:15 http://www.biomedcentral.com/1471-2288/4/15
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conditions that are rapidly becoming epidemic in some
developing countries [25].
Finally, the fact that only two similar languages (Spanish
and Portuguese) are spoken in Latin America is essential
for communication among all participants of the project.
The epidemiological transition is leading to sharp
increases in chronic diseases in developing countries.
COPD and overweight/obesity, for example, are predicted
to become leading causes of morbidity and mortality in
the near future [25]. Research findings from developed
countries cannot be automatically extrapolated to popula-
tions which, for example, may be exposed to domestic
biomass pollution, home-made cigarettes or fetal or child-
hood malnutrition. Thus, experience in population-based
surveys of chronic diseases and their risk factors will
become increasingly important in coming years. The
PLATINO project shows that researchers from less devel-
oped countries can carry out complex studies involving
several countries, and providing robust results with wide
policy implications.
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